RT Journal Article
SR Electronic
T1 Recurrent and Concurrent Prediction of Longitudinal Progression of Stargardt Atrophy and Geographic Atrophy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.11.24302670
DO 10.1101/2024.02.11.24302670
A1 Mishra, Zubin
A1 Wang, Ziyuan
A1 Xu, Emily
A1 Xu, Sophia
A1 Majid, Iyad
A1 Sadda, SriniVas R.
A1 Hu, Zhihong Jewel
YR 2024
UL http://medrxiv.org/content/early/2024/02/13/2024.02.11.24302670.abstract
AB Stargardt disease and age-related macular degeneration are the leading causes of blindness in the juvenile and geriatric populations, respectively. The formation of atrophic regions of the macula is a hallmark of the end-stages of both diseases. The progression of these diseases is tracked using various imaging modalities, two of the most common being fundus autofluorescence (FAF) imaging and spectral-domain optical coherence tomography (SD-OCT). This study seeks to investigate the use of longitudinal FAF and SD-OCT imaging (month 0, month 6, month 12, and month 18) data for the predictive modelling of future atrophy in Stargardt and geographic atrophy. To achieve such an objective, we develop a set of novel deep convolutional neural networks enhanced with recurrent network units for longitudinal prediction and concurrent learning of ensemble network units (termed ReConNet) which take advantage of improved retinal layer features beyond the mean intensity features. Using FAF images, the neural network presented in this paper achieved mean (± standard deviation, SD) and median Dice coefficients of 0.895 (± 0.086) and 0.922 for Stargardt atrophy, and 0.864 (± 0.113) and 0.893 for geographic atrophy. Using SD-OCT images for Stargardt atrophy, the neural network achieved mean and median Dice coefficients of 0.882 (± 0.101) and 0.906, respectively. When predicting only the interval growth of the atrophic lesions with FAF images, mean (± SD) and median Dice coefficients of 0.557 (± 0.094) and 0.559 were achieved for Stargardt atrophy, and 0.612 (± 0.089) and 0.601 for geographic atrophy. The prediction performance in OCT images is comparably good to that using FAF which opens a new, more efficient, and practical door in the assessment of atrophy progression for clinical trials and retina clinics, beyond widely used FAF. These results are highly encouraging for a high-performance interval growth prediction when more frequent or longer-term longitudinal data are available in our clinics. This is a pressing task for our next step in ongoing research.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01977846Funding StatementThis work was supported by the National Eye Institute of the National Institutes of Health under Award Number R21EY029839.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the Stargardt data, the ethics reviews and institutional review board approvals were obtained from the local ethics committees of all the nine participating institutions, i.e., The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland (JHU); Greater Baltimore Medical Centre, Baltimore, Maryland (GBMC); Scheie Eye Institute, University of Philadelphia, Philadelphia, Pennsylvania (PENN); Retina Foundation of the Southwest, Dallas, Texas (RFSW); Moran Eye Centre, Salt Lake City, Utah (MEC); Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio (CC); Moorfields Eye Hospital, London, UK (MEH, UK); Universite de Paris 06, Institut national de la sante et de la recherche medicale, Paris, France (INSERM, France); and Eberhard-Karls University Eye Hospital, Tuebingen, Germany (EKU, Germany). For the geographic atrophy data, ethics review and institutional review board approval from the University of California, Los Angeles were obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to the patients’ privacy and the violation of informed consent but are available from the corresponding author on reasonable request.